If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> UROLOGY<br /> EMJ Urol. 2019 Suppl 2 • europeanmedical-journal.com<br /> INSIDE<br /> A Multi-Disciplinary Review of the Evidence<br /> Supporting Metastasis-Free Survival (MFS)<br /> and the Benefit of Delaying Metastasis<br /> in High-Risk Non-Metastatic Castration-<br /> Resistant Prostate Cancer (nmCRPC)<br /> A Multi-Disciplinary Review of the Evidence<br /> Supporting Metastasis-Free Survival (MFS)<br /> and the Benefit of Delaying Metastasis in<br /> High-Risk Non-Metastatic Castration-Resistant<br /> Prostate Cancer (nmCRPC)<br /> Authors: Stéphane Oudard,1 Álvaro Juárez Soto2<br /> 1. Oncology Department, European Georges Pompidou Hospital, University Paris<br /> Descartes Paris 5, Paris, France<br /> 2. Urology Service, Hospital Universitario de Jerez de la Frontera, Cádiz, Spain<br /> Disclosure: Stéphane Oudard has received honoraria from Astellas, Janssen,<a title="EMJ Urol. 2019 Suppl 2 page 1" href="http://viewer.zmags.com/publication/f1a69dea?page=1"> UROLOGY EMJ Urol. 2019 Suppl 2 • europeanmedical-</a> <a title="EMJ Urol. 2019 Suppl 2 page 2" href="http://viewer.zmags.com/publication/f1a69dea?page=2"> A Multi-Disciplinary Review of the Evidence </a> <a title="EMJ Urol. 2019 Suppl 2 page 3" href="http://viewer.zmags.com/publication/f1a69dea?page=3"> INTRODUCTION Prostate cancer is the second most c</a> <a title="EMJ Urol. 2019 Suppl 2 page 4" href="http://viewer.zmags.com/publication/f1a69dea?page=4"> be confirmed by imaging, including bone and comput</a> <a title="EMJ Urol. 2019 Suppl 2 page 5" href="http://viewer.zmags.com/publication/f1a69dea?page=5"> followed for OS, demonstration of improved OS is </a> <a title="EMJ Urol. 2019 Suppl 2 page 6" href="http://viewer.zmags.com/publication/f1a69dea?page=6"> Table 2: Safety and tolerability in Phase III tri</a> <a title="EMJ Urol. 2019 Suppl 2 page 7" href="http://viewer.zmags.com/publication/f1a69dea?page=7"> benefits and a favourable safety profile were obser</a> <a title="EMJ Urol. 2019 Suppl 2 page 8" href="http://viewer.zmags.com/publication/f1a69dea?page=8"> A 3.5 3.0 2.5 B 2.0 Hazard ratio 2.0 1.5 Haz</a> <a title="EMJ Urol. 2019 Suppl 2 page 9" href="http://viewer.zmags.com/publication/f1a69dea?page=9"> chemotherapy and first symptomatic skeletal ev</a> <a title="EMJ Urol. 2019 Suppl 2 page 10" href="http://viewer.zmags.com/publication/f1a69dea?page=10"> suggests that earlier treatment of nmCRPC may be </a> <a title="EMJ Urol. 2019 Suppl 2 page 11" href="http://viewer.zmags.com/publication/f1a69dea?page=11"> sistant prostate cancer: Considera- tions for met</a>